shutterstock_756403858-[Converted].png

We are a
Life Sciences Company that Cares

We are transforming the drug discovery and development process and accelerating the creation of life-changing psilocybin drugs on behalf of patients.

Mynd_PPD.png

Our Focus is to provide objective, quantitative diagnoses and monitoring for some of the world’s most prevalent diseases including:

POST PARTUM DEPRESSION
+LEARN MORE BELOW
CSE: MYND / OTC: MYNDF
mynd-header_home.jpg

The Unspoken Plight in Women’s Health, PPD

What if we told you we could diagnose Post Partum Depression early so you don’t end up in crisis?

Subtract.png

Dare to Think Different?

“I held concerns about being branded a ‘bad mother’ for requiring medication.”

25_bw-wht.png
EVELYN • MOTHER OF 3

Normalizing Women’s Health

The birth of a baby can trigger a jumble of powerful emotions, from excitement and joy to fear and anxiety. But it can also result in something you might not expect — depression.

Sadly, it is believed that postpartum depression is much more common than these statistics reveal. Some medical experts believe that the rate of postpartum depression could be at least twice as much than what is actually reported and diagnosed. If symptoms go unreported and untreated, they cannot be accounted for in global health statistics.


 

mynd-ppd.png

Early & Correct
Diagnosis is Key

Currently, the only way to diagnose is through a Postnatal Depression Scale Questionnaire, a subjective self-reporting of symptoms.

We are developing a PPD Biomarker test that will objectively detect the presence of a certain protein in the blood that needs to be present to fight the inflammation that causes PPD. Allowing for an early diagnosis and ultimately a higher chance of disease prevention.

 

Untitled-1.png

Many Women Suffer in Silence, dismissing their struggles as a normal part of pregnancy and childbirth and failing to seek care. Early detection during pregnancy is essential for effective treatment post-delivery. Greater awareness and understanding can lead to better outcomes for women and their babies.

We have designed a Biomarker that can early identify PPD.

Crisis no longer needs to be the diagnosis.

An estimated 1 in 5 women experience Post-Partum depression. As many as half of PPD in new mothers go undiagnosed because of conflict in privacy and not wanting to disclose to close family members

E6805_04-22.jpg

Through our clinical trials we anticipate being able to diagnose with our biomarker and eventually our drug candidates will provide a pathway to getting better.

LEARN ABOUT DRUG CANDIDATES

Untitled-1.jpg

Welcome to the future, where the reconnection of lost pathways is a possibility, are you ready to heal your mynd?

Post-Partum Depression isn’t the only thing on our mynd. Explore our other groundbreaking initiatives on neuroinflammatory diseases.

WHAT'S IN OUR PIPELINE?